CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for WPD Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

WPD Pharmaceuticals Inc
Suite 1080, 789 West Pender Street
Phone: (604) 428-7050p:604 428-7050 VANCOUVER, BC  V6C 1H2  Canada Ticker: WBIOWBIO
Business Summary
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer MariuszOlejniczak 12/24/2019 12/24/2019
Chief Financial Officer MichaelMalana 8/10/2020 8/10/2020
Canadian Vice President of Legal, Corporate Secretary, Director Liam L.Corcoran 12/20/2019 6/23/2017
3 additional Officers and Directors records available in full report.

Business Names
Business Name
8SV1
SPW.H
WBIO
WET.H
WVC.H

General Information
Outstanding Shares: 113,438,244 (As of 9/30/2023)
Stock Exchange: CNQ
Fax Number: (604) 428-7050


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024